9MST の概要
| エントリーDOI | 10.2210/pdb9mst/pdb |
| 分子名称 | Epidermal growth factor receptor, Befotertinib, bound form (3 entities in total) |
| 機能のキーワード | cancer, drug development, drug resistance, signaling, transferase |
| 由来する生物種 | Homo sapiens (human) |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 37873.75 |
| 構造登録者 | |
| 主引用文献 | Damghani, T.,Chitnis, S.P.,Abidakun, O.A.,Patel, K.B.,Lin, K.S.,Ouellette, E.A.,Lantry, A.M.,Heppner, D.E. Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies. J.Med.Chem., 68:17917-17932, 2025 Cited by PubMed Abstract: Targeted covalent inhibitors (TCIs) are actively pursued in drug discovery due to their prolonged target engagement and clinical efficacy. Although kinetic parameters provide a path to their optimization, systematic design strategies and practical guidance remain underexplored. In this study, the EGFR kinase is deployed as a model system to elucidate structural and functional determinants critical for directing the optimization of irreversible TCIs. Functional analyses reveal a two-phase optimization process, underscoring the importance of balancing─rather than maximizing─the inactivation efficiency rate (/). Selective inhibition of the oncogenic L858R/T790M mutant over the wild-type is achieved by tuning this balance, particularly for TCIs exhibiting the fastest /. Structural studies indicate that certain hydrophobic and hydrophilic interactions are associated with L858R/T790M selectivity, offering insights into structure-guided design. These results offer a broadly applicable approach for prioritizing compounds and support the integration of kinetic and selectivity data in TCI discovery campaigns. PubMed: 40801664DOI: 10.1021/acs.jmedchem.5c01661 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.57 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
をダウンロード
